Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)
Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
The use of Iressa will result in a greater than 20% response rate in patients with
nonresectable adrenocortical cancer who have previously been treated with one other form of
systemic therapy (either Mitotane or chemotherapy).
Phase:
Phase 2
Details
Lead Sponsor:
Dartmouth-Hitchcock Medical Center
Collaborators:
AstraZeneca Dana-Farber Cancer Institute Kentuckiana Cancer Institute M.D. Anderson Cancer Center